Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized relaxin family peptide receptor 1 (RXFP1) receptor agonists reported to be potentially useful for the treatment of heart failure.
Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has disclosed new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors that are potentially useful for the treatment of cancer.
Innovo Therapeutics Inc. has divulged sulfonamide derivatives acting as N-myristoyltransferase 1 (NMT1) inhibitors found to be potentially useful for the treatment of cancer, protozoal and viral infection.
Leto Laboratories Co. Ltd. has identified macro cyclic peptides acting as calcitonin receptor (CALCR; CT-R) and amylin dual receptor agonists reported to be potentially useful for the treatment of atherosclerosis, type 1 diabetes, dyspepsia, myocardial infarction, obesity and more.
Ubiquitin-specific protease 7 (USP7) is a central regulator of multiple oncogenic pathways and is associated with tumor aggressiveness and poor prognosis across several cancer types. Researchers from Molecure SA characterized the preclinical profile of OAT-4828, a selective USP7 inhibitor with antiproliferative activity.
Glucagon-like peptide 1 receptor agonist (GLP-1RA) compounds have become game changers in the treatment of obesity, but they have limitations due to long-term efficacy, lean mass preservation and tolerability in certain populations. Mitorx Therapeutics Ltd. has presented data for MTRX-31 (Myo-004), a mitochondrial-targeted compound that provides an alternative mode of action for treating obesity.
Researchers from Verdiva Bio Ltd. and collaborators recently presented preclinical data on VRB-103, an oral amylin analogue, comparing its profile with those of cagrilintide and eloralintide, two subcutaneously administered analogues currently in clinical development.
CD45RC is an isoform of protein tyrosine phosphatase receptor type C, a protein that plays a key role in regulating antigen receptor signaling in T and B cells. While it is expressed on most circulating B cells, it is only highly expressed on Th1 precursors, Th1 cells and T effector memory CD45RA+ cells (TEMRA).
Researchers from Ractigen Therapeutics Co. Ltd. presented preclinical data on LiCO-saUcp1, a small activating RNA (saRNA) therapeutic designed to upregulate UCP1 expression in adipose tissue.
RSS
